Lack of effect of Candida albicans mannan on development of protective immune responses in experimental murine candidiasis
- PMID: 7507901
- PMCID: PMC186170
- DOI: 10.1128/iai.62.2.738-741.1994
Lack of effect of Candida albicans mannan on development of protective immune responses in experimental murine candidiasis
Abstract
Candida albicans mannoprotein (MAN) administered to mice before or during immunization with viable C. albicans downregulates MAN-specific delayed hypersensitivity. In the experiments reported here we determined the effect of MAN downregulation on protective immunity in minimally immunized mice, i.e., mice exposed to C. albicans either intradermally or intragastrically, and in maximally immunized mice, i.e., mice immunized by a combination of intradermal and intragastric exposure, in experimental systemic candidiasis. MAN suppression did not induce statistically significant alterations in the protective responses in experimental candidiasis, although 8 of 12 groups of mice treated with MAN had fewer CFU of C. albicans in their kidneys than their non-MAN-treated counterparts. The results emphasize the lack of correlation of delayed hypersensitivity with protection in candidiasis and suggest that MAN may contain epitopes involved in the protective response.
Similar articles
-
Abrogation of suppression of delayed hypersensitivity induced by Candida albicans-derived mannan by treatment with monophosphoryl lipid A.Infect Immun. 1993 May;61(5):2122-30. doi: 10.1128/iai.61.5.2122-2130.1993. Infect Immun. 1993. PMID: 8478102 Free PMC article.
-
Characterization of Candida albicans mannan-induced, mannan-specific delayed hypersensitivity suppressor cells.Infect Immun. 1990 Aug;58(8):2613-20. doi: 10.1128/iai.58.8.2613-2620.1990. Infect Immun. 1990. PMID: 2142482 Free PMC article.
-
In vivo immune responses to Candida albicans modified by treatment with recombinant murine gamma interferon.Infect Immun. 1989 Jun;57(6):1800-8. doi: 10.1128/iai.57.6.1800-1808.1989. Infect Immun. 1989. PMID: 2498208 Free PMC article.
-
Protective antigens and mechanisms of anti-Candida immunity.Nihon Ishinkin Gakkai Zasshi. 2000;41(4):219. doi: 10.3314/jjmm.41.219. Nihon Ishinkin Gakkai Zasshi. 2000. PMID: 11064318 Review.
-
Defining criteria for anti-mannan antibodies to protect against candidiasis.Curr Mol Med. 2005 Jun;5(4):383-92. doi: 10.2174/1566524054022576. Curr Mol Med. 2005. PMID: 15977994 Review.
Cited by
-
A mannoprotein constituent of Candida albicans that elicits different levels of delayed-type hypersensitivity, cytokine production, and anticandidal protection in mice.Infect Immun. 1994 Dec;62(12):5353-60. doi: 10.1128/iai.62.12.5353-5360.1994. Infect Immun. 1994. PMID: 7960114 Free PMC article.
-
Candida albicans primes TLR cytokine responses through a Dectin-1/Raf-1-mediated pathway.J Immunol. 2013 Apr 15;190(8):4129-35. doi: 10.4049/jimmunol.1202611. Epub 2013 Mar 8. J Immunol. 2013. PMID: 23475217 Free PMC article.
-
Alterations in frequency of interleukin-2 (IL-2)-, gamma interferon-, or IL-4-secreting splenocytes induced by Candida albicans mannan and/or monophosphoryl lipid A.Infect Immun. 1998 Apr;66(4):1392-9. doi: 10.1128/IAI.66.4.1392-1399.1998. Infect Immun. 1998. PMID: 9529058 Free PMC article.
-
Production and function of cytokines in natural and acquired immunity to Candida albicans infection.Microbiol Rev. 1995 Dec;59(4):646-72. doi: 10.1128/mr.59.4.646-672.1995. Microbiol Rev. 1995. PMID: 8531890 Free PMC article. Review.
-
Candida albicans-derived mannoproteins activate NF-κB in reporter cells expressing TLR4, MD2 and CD14.PLoS One. 2017 Dec 27;12(12):e0189939. doi: 10.1371/journal.pone.0189939. eCollection 2017. PLoS One. 2017. PMID: 29281684 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical